Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Algenpantucel-L - NewLink Genetics Corporation

Drug Profile

Algenpantucel-L - NewLink Genetics Corporation

Alternative Names: HAPa; HyperAcute Pancreas; HyperAcute-Pancreas-Immunotherapy; Pancreatic cancer vaccine - NewLink Genetics

Latest Information Update: 08 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies; DNA vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer

Most Recent Events

  • 26 Feb 2019 NewLink Genetics Corporation terminates the phase III PILLAR trial in Pancreatic cancer (Combination therapy, Inoperable/Unresectable) in USA (Intradermal) (NCT01836432)
  • 30 Jun 2016 NewLink Genetics terminates a phase II trial in Pancreatic cancer (Combination therapy) in USA (NCT02405585)
  • 09 May 2016 NewLink Genetics does not meet the primary endpoint in a phase III IMPRESS trial in Pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top